BBNX
Bearish signalScored 2026-09-28 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Beta Bionics, Inc.
- Nom
- Beta Bionics, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $862.0M
- Employés
- 422
- PDG
- Sean T. Saint
- Site web
- https://www.betabionics.com
- Marché
- DXCMMMEDMNKDNVOORMPPODD
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 28 938 titres (~583 529,53 $ US)
- Insiders
- Jones ChristySaint Sean
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,338,754
Avg sell (VWAP, 90d window) $19.47 vs last close $18.96 (-2.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,615,667 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-22
- Liquidity
- Liquid $29,281,110/day · 20d vol
- Last synced
-
2026-10-02 21:10:09
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-14 | Hopman Mark | Sell · S | 775 | $17.35 | $13,446 | Form 4 |
| 2026-10-01 | Hopman Mark | Sell · S | 370 | $18.96 | $7,015 | Form 4 |
| 2026-09-22 | Jones Christy | Sell · S · 10b5-1 | 6,430 | $23.00 | $147,890 | Form 4 |
| 2026-09-16 | Hopman Mark | Sell · S · 10b5-1 | 30,779 | $20.13 | $619,640 | Form 4 |
| 2026-09-16 | Mensinger Mike | Sell · S · 10b5-1 | 2,650 | $22.00 | $58,300 | Form 4 |
| 2026-09-14 | Hopman Mark | Sell · S · 10b5-1 | 775 | $15.52 | $12,028 | Form 4 |
| 2026-09-09 | Hopman Mark | Sell · S · 10b5-1 | 35,994 | $18.46 | $664,550 | Form 4 |
| 2026-09-03 | Saint Sean | Sell · S · 10b5-1 | 5,641 | $20.08 | $113,259 | Form 4 |
| 2026-09-02 | Feider Stephen | Sell · S | 6,675 | $19.11 | $127,580 | Form 4 |
| 2026-09-02 | Hopman Mark | Sell · S | 5,327 | $19.11 | $101,815 | Form 4 |
| 2026-09-02 | Mensinger Mike | Sell · S | 4,375 | $19.11 | $83,620 | Form 4 |
| 2026-09-02 | Russell Steven Jon | Sell · S | 4,221 | $19.11 | $80,676 | Form 4 |
| 2026-09-02 | Saint Sean | Sell · S | 16,867 | $19.11 | $322,381 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-28 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
BBNX presents a deeply unfavorable risk/reward profile: a catalyst score of 0 driven by active securities class action lawsuits and heavy insider selling leaves no bullish event-driven thesis whatsoever.
The first sentence of the analysis written for BBNX on 2026-09-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 8.66 · operating margin -72% — readings disagree
Suggested stop 15.93, nearest stored support minus 0.5 ATR(16.0% under the last close). Reward/risk to the next stored resistance is 0.59. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.4% | 55.1% | 52.6% | 100.0% | |
| Ebit Margin | -73.0% | -84.1% | -367.6% | -36169.8% | |
| Ebitda Margin | -70.1% | -82.3% | -357.4% | -35418.4% | |
| Operating Profit Margin | -71.5% | -69.5% | -298.9% | -36784.4% | |
| Pretax Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Continuous Operations Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Net Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Bottom Line Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Current Ratio | 8.663 | 6.285 | 9.771 | 3.208 | |
| Quick Ratio | 7.961 | 5.656 | 9.654 | 3.208 | |
| Solvency Ratio | -1.710 | -0.728 | -0.834 | -0.308 | |
| Cash Ratio | 1.021 | 1.439 | 2.505 | 3.119 | |
| Price To Earnings Ratio | -16.834 | -18.461 | -22.942 | -15.649 | |
| Price To Earnings Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Price To Earnings Diluted Ratio | -16.834 | -18.461 | -22.942 | -15.649 | |
| Price To Earnings Diluted Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Price To Book Ratio | 4.294 | 13.324 | 17.280 | -5.956 | |
| Price To Sales Ratio | 12.318 | 15.551 | 84.432 | 5,657.912 | |
| Price To Free Cash Flow Ratio | -21.965 | -19.601 | -30.833 | -16.608 | |
| Price To Operating Cash Flow Ratio | -24.250 | -20.980 | -31.215 | -16.821 | |
| Debt To Assets Ratio | 0.022 | 0.048 | 0.038 | 0.116 | |
| Debt To Equity Ratio | 0.025 | 0.095 | 0.072 | -0.024 | |
| Debt To Capital Ratio | 0.025 | 0.087 | 0.067 | -0.025 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.143 | 1.969 | 1.878 | -0.209 | |
| Working Capital Turnover Ratio | 0.575 | 0.636 | 0.213 | 0.000 | |
| Operating Cash Flow Ratio | -1.647 | -2.283 | -3.059 | -6.786 | |
| Operating Cash Flow Sales Ratio | -0.508 | -0.741 | -2.705 | -336.358 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | 1.070 | 1.012 | 1.013 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -35.027 | -4,528.500 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -4,703.143 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -26.507 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -6.973 | -6.654 | -7.683 | -14.568 | |
| Capital Expenditure Coverage Ratio | -9.614 | -14.219 | -80.709 | -77.990 | |
| Dividend Paid And Capex Coverage Ratio | -9.614 | -14.219 | -80.709 | -77.990 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -17.215 | -18.461 | -23.101 | -15.603 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.4% | ▲0.3% | ▼-10.4% |
| Ebit Margin | -73.0% | ▲11.1% | ▲9100.6% |
| Ebitda Margin | -70.2% | ▲12.2% | ▲8911.9% |
| Operating Profit Margin | -71.5% | ▼-2.0% | ▲9234.5% |
| Pretax Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Continuous Operations Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Net Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Bottom Line Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Current Ratio | 8.663 | ▲2.378 | ▲1.681 |
| Quick Ratio | 7.961 | ▲2.305 | ▲1.341 |
| Solvency Ratio | -1.710 | ▼-0.982 | ▼-0.815 |
| Cash Ratio | 1.021 | ▼-0.418 | ▼-1.000 |
| Price To Earnings Ratio | -16.834 | ▲1.627 | ▲1.637 |
| Price To Earnings Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Forward Price To Earnings Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Price To Earnings Diluted Ratio | -16.834 | ▲1.627 | ▲1.637 |
| Price To Earnings Diluted Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Price To Book Ratio | 4.294 | ▼-9.030 | ▼-2.942 |
| Price To Sales Ratio | 12.318 | ▼-3.233 | ▼-1430.235 |
| Price To Free Cash Flow Ratio | -21.965 | ▼-2.364 | ▲0.287 |
| Price To Operating Cash Flow Ratio | -24.250 | ▼-3.270 | ▼-0.933 |
| Debt To Assets Ratio | 0.022 | ▼-0.026 | ▼-0.034 |
| Debt To Equity Ratio | 0.025 | ▼-0.070 | ▼-0.017 |
| Debt To Capital Ratio | 0.025 | ▼-0.062 | ▼-0.014 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.143 | ▼-0.826 | ▼-0.052 |
| Working Capital Turnover Ratio | 0.575 | ▼-0.061 | ▲0.219 |
| Operating Cash Flow Ratio | -1.647 | ▲0.636 | ▲1.797 |
| Operating Cash Flow Sales Ratio | -0.508 | ▲0.233 | ▲84.570 |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | ▲0.034 | ▲0.054 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲1140.882 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲1175.786 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.627 |
| Operating Cash Flow Coverage Ratio | -6.973 | ▼-0.319 | ▲1.996 |
| Capital Expenditure Coverage Ratio | -9.614 | ▲4.605 | ▲36.019 |
| Dividend Paid And Capex Coverage Ratio | -9.614 | ▲4.605 | ▲36.019 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -17.215 | ▲1.246 | ▲1.380 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.23B | $1.01B | $1.01B | $1.01B | |
| Enterprise value | $1.21B | $989.6M | $990.4M | $989.2M | |
| EV / Sales | 12.08x | 15.20x | 82.57x | 5526.39x | |
| EV / Op. cash flow | -23.77x | -20.50x | -30.53x | -16.43x | |
| EV / Free cash flow | -21.53x | -19.15x | -30.15x | -16.22x | |
| EV / EBITDA | -17.21x | -18.46x | -23.10x | -15.60x | |
| Net debt / EBITDA | 0.34x | 0.43x | 0.52x | 0.37x | |
| Current ratio | 8.66x | 6.29x | 9.77x | 3.21x | |
| Income quality | 0.70x | 0.88x | 0.74x | 0.93x | |
| Graham net-net | $5 | $1 | $1 | -$4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $237.0M | $111.8M | $93.0M | $19.6M | |
| Invested capital | $252.2M | $123.2M | $99.2M | $26.5M | |
| Return on assets | -22.3% | -36.6% | -40.1% | -182.3% | |
| Operating ROA | -30.0% | -34.9% | -49.3% | 0.0% | |
| Return on tangible assets | -22.3% | -36.6% | -40.1% | -182.3% | |
| Return on equity | -25.5% | -72.0% | -75.2% | 38.1% | |
| Return on invested capital | -23.9% | -34.8% | -35.6% | -238.3% | |
| Return on capital employed | -24.1% | -35.2% | -36.1% | -247.0% | |
| Earnings yield | -5.9% | -5.4% | -4.4% | -6.4% | |
| Free cash flow yield | -4.6% | -5.1% | -3.2% | -6.0% | |
| Capex / Op. cash flow | -10.4% | -7.0% | -1.2% | -1.3% | |
| Capex / Depreciation | 184.2% | 148.7% | 19.2% | 37.0% | |
| Capex / Sales | 5.3% | 5.2% | 3.4% | 431.3% | |
| SG&A / Sales | 92.2% | 84.4% | 201.9% | 18712.3% | |
| R&D / Sales | 34.7% | 40.2% | 149.6% | 17557.5% | |
| Stock comp / Sales | 16.3% | 9.8% | 47.2% | 3407.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 72d | 67d | 135d | 0d | |
| Days payables outstanding | 41d | 36d | 75d | 0d | |
| Operating cycle | 250d | 234d | 215d | 0d | |
| Cash conversion cycle | 209d | 198d | 140d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-27 Faruqi & Faruqi, LLP Urges Beta Bionics (BBNX) Investors to Seek Counsel Before November 3, 2026 Lead Plaintiff Deadline in the Securities Class Action Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Beta Bionics to Contact Him Directly to Discuss Their Options New York, New York--(Newsfile Corp. - September 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). [You may also click here for additional information] WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the securities class action brought on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period").
- 2026-09-26 ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX New York, New York--(Newsfile Corp. - September 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-09-25 Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.
- 2026-09-25 ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX New York, New York--(Newsfile Corp. - September 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-09-25 Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Beta Bionics, Inc. (BBNX) on November 3, 2026 New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.
- 2026-09-25 Beta Bionics, Inc. Sued for Securities Law Violations; Investors Who Lost Money Should Contact Block & Leviton LLP Boston, Massachusetts--(Newsfile Corp. - September 25, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its executives. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover those losses.
- 2026-09-25 DEADLINE ALERT for DKS and BBNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
- 2026-09-25 DEADLINE ALERT for DKS, BBNX, FCEL, and LINC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
- 2026-09-25 Beta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company''s common stock between July 30, 2025 and February 24, 2026.
- 2026-09-25 Kaplan Fox Encourages Beta Bionics, Inc. (NASDAQ: BBNX) Investors with Losses to Contact the Firm Before November 3, 2026 NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).